Phase I
Imaging pancreatic beta-cells with PET neuroimaging agent 11C-PHNO
- Study HIC#:2000021287
- Last Updated:11/11/2022
We are conducting a PET imaging study to develop a way to measure the number of insulin secreting cells in the pancreas. This study is intended for people diagnosed with Type 2 Diabetes who are otherwise in good physical health and well controlled on insulin. The study requires 2-3 visits over several weeks.
- Age18 years - 65 years
- GenderBoth
- Start Date09/05/2017
- End Date07/31/2021
Trial Purpose and Description
As per HIC-approved protocol, 1411014915 (Specific Aim 1), this proposal will continue to explore whether an imaging agent already in use for human neuroimaging, specifically 11C-PHNO, would also be useful for measuring BCM.
Eligibility Criteria
Ages 18-65 (males and females) -Type 2 Diabetes diagnosis -Body mass index (BMI) of 18-35 kg/m2 -Not claustrophobic -Not taking anticoagulant medication Healthy controls are welcome
